{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:09:31Z","timestamp":1780337371876,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T00:00:00Z","timestamp":1683331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016966","name":"Bethune Charitable Foundation","doi-asserted-by":"publisher","award":["Z04JKM2021005"],"award-info":[{"award-number":["Z04JKM2021005"]}],"id":[{"id":"10.13039\/100016966","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017366","name":"Key Research and Development Program of Heilongjiang","doi-asserted-by":"publisher","award":["2022ZX02C09"],"award-info":[{"award-number":["2022ZX02C09"]}],"id":[{"id":"10.13039\/100017366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274028"],"award-info":[{"award-number":["82274028"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004027","name":"Heilongjiang Postdoctoral","doi-asserted-by":"publisher","award":["LBH-Q20031"],"award-info":[{"award-number":["LBH-Q20031"]}],"id":[{"id":"10.13039\/501100004027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010722","name":"Harbin Medical University","doi-asserted-by":"publisher","award":["HYD2020JQ0018"],"award-info":[{"award-number":["HYD2020JQ0018"]}],"id":[{"id":"10.13039\/100010722","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.biopha.2023.114858","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T17:18:03Z","timestamp":1683739083000},"page":"114858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients"],"prefix":"10.1016","volume":"163","author":[{"given":"Jian","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.biopha.2023.114858_bib1","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","article-title":"Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group","volume":"103","author":"Ad\u00e8s","year":"2018","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.biopha.2023.114858_bib2","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1039\/c9mt00308h","article-title":"Therapeutic strategy of arsenic trioxide in the fight against cancers and other diseases","volume":"12","author":"Wang","year":"2020","journal-title":"Metallomics"},{"issue":"14","key":"10.1016\/j.biopha.2023.114858_bib3","doi-asserted-by":"crossref","first-page":"23905","DOI":"10.18632\/oncotarget.14733","article-title":"Metabolism, toxicity and anticancer activities of arsenic compounds","volume":"8","author":"Khairul","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2023.114858_bib4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/03602532.2020.1791173","article-title":"Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts","volume":"52","author":"Maimaitiyiming","year":"2020","journal-title":"Drug Metab. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2023.114858_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00280-009-1169-4","article-title":"A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment","volume":"66","author":"Sweeney","year":"2010","journal-title":"Cancer Chemother. Pharm."},{"issue":"1","key":"10.1016\/j.biopha.2023.114858_bib6","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-021-00205-6","article-title":"Importance of monitoring arsenic methylation metabolism in acute promyelocytic leukemia patients receiving the treatment of arsenic trioxide","volume":"10","author":"Zheng","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114858_bib7","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/jat.4127","article-title":"Association between the polymorphism of three genes involved in the methylation and efflux of arsenic (As3MT, MRP1, and P-gp) with lung cancer in a Mexican cohort","volume":"41","author":"Recio-Vega","year":"2021","journal-title":"J. Appl. Toxicol."},{"issue":"43","key":"10.1016\/j.biopha.2023.114858_bib8","doi-asserted-by":"crossref","first-page":"33404","DOI":"10.1074\/jbc.M007030200","article-title":"The MRP2\/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic","volume":"275","author":"Kala","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2023.114858_bib9","first-page":"1000","article-title":"Functional expression of multidrug resistance protein 4 MRP4\/ABCC4, SLAS discovery","volume":"24","author":"Hardy","year":"2019","journal-title":"Adv. Life Sci. R. D."},{"issue":"6","key":"10.1016\/j.biopha.2023.114858_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14740338.3.6.589","article-title":"Arsenic trioxide in the treatment of haematological malignancies","volume":"3","author":"Kwong","year":"2004","journal-title":"Expert Opin. Drug Saf."},{"issue":"10","key":"10.1016\/j.biopha.2023.114858_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9103342","article-title":"Incidence of differentiation syndrome associated with treatment regimens in acute myeloid leukemia: a systematic review of the literature","volume":"9","author":"Gasparovic","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2023.114858_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115299","article-title":"Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia","volume":"409","author":"Wang","year":"2020","journal-title":"Toxicol. Appl. Pharm."},{"key":"10.1016\/j.biopha.2023.114858_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.895777","article-title":"Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia","volume":"12","author":"Wen","year":"2022","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114858_bib14","doi-asserted-by":"crossref","first-page":"7262","DOI":"10.4238\/2014.September.5.11","article-title":"Torasemide reduces dilated cardiomyopathy, complication of arrhythmia, and progression to heart failure","volume":"13","author":"Han","year":"2014","journal-title":"Genet. Mol. Res.: GMR"},{"issue":"18","key":"10.1016\/j.biopha.2023.114858_bib15","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/cncr.32196","article-title":"Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia","volume":"125","author":"Chamoun","year":"2019","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.114858_bib16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1389200223666220401092112","article-title":"A comprehensive review of the pharmacologic perspective on loop diuretic drug interactions with therapeutically used drugs","volume":"23","author":"Maideen","year":"2022","journal-title":"Curr. Drug Metab."},{"issue":"2","key":"10.1016\/j.biopha.2023.114858_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.15386\/mpr-1130","article-title":"Influence of concomitant medication on plasma concentration of amiodarone in patients with atrial fibrillation - a pilot study","volume":"92","author":"Neag","year":"2019","journal-title":"Med Pharm. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2023.114858_bib18","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/nep.12838","article-title":"Impact of the induced organic anion transporter 1 (Oat1) renal expression by furosemide on the pharmacokinetics of organic anions","volume":"22","author":"Severin","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"7","key":"10.1016\/j.biopha.2023.114858_bib19","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/bjp.2008.343","article-title":"Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4","volume":"155","author":"El-Sheikh","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.biopha.2023.114858_bib20","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/bcp.13728","article-title":"Loop diuretics decrease the renal elimination rate and increase the plasma levels of trimethylamine-N-oxide","volume":"84","author":"Latkovskis","year":"2018","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2023.114858_bib21","article-title":"Pharmacokinetic characteristics, tissue bioaccumulation and toxicity profiles of oral arsenic trioxide in rats: implications for the treatment and risk assessment of acute promyelocytic","volume":"12","author":"Liu","year":"2021","journal-title":"Leuk., Front. Pharmacol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114858_bib22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-018-3606-8","article-title":"Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia","volume":"82","author":"Gao","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114858_bib23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1080\/17512433.2021.1938549","article-title":"Effect of renal impairment on arsenic accumulation, methylation capacity, and safety in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide","volume":"14","author":"Zhao","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114858_bib24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jinorgbio.2011.11.009","article-title":"Arsenic-glutathione conjugate transport by the human multidrug resistance proteins (MRPs\/ABCCs)","volume":"108","author":"Leslie","year":"2012","journal-title":"J. Inorg. Biochem."},{"issue":"9","key":"10.1016\/j.biopha.2023.114858_bib25","first-page":"3345","article-title":"Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.biopha.2023.114858_bib26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/17512433.2021.1893940","article-title":"Characteristics and clinical influence factors of arsenic species in plasma and their role of arsenic species as predictors for clinical efficacy in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide","volume":"14","author":"Guo","year":"2021","journal-title":"Expert Rev. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114858_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2174\/1389200223666220401092112","article-title":"A comprehensive review of the pharmacologic perspective on loop diuretic drug interactions with therapeutically used drugs","volume":"23","author":"Maideen","year":"2022","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.biopha.2023.114858_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10534-015-9901-5","article-title":"Exceptions in patterns of arsenic compounds in urine of acute promyelocytic leukaemia patients treated with As2O3","volume":"29","author":"\u0160lejkovec","year":"2016","journal-title":"Biometals"},{"issue":"7","key":"10.1016\/j.biopha.2023.114858_bib29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1124\/dmd.105.003780","article-title":"Tissue distribution and hepatic and renal ontogeny of the multidrug resistance-associated protein (Mrp) family in mice","volume":"33","author":"Maher","year":"2005","journal-title":"Drug Metab. Dispos.: Biol. Fate Chem."},{"issue":"2","key":"10.1016\/j.biopha.2023.114858_bib30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1124\/mol.113.091314","article-title":"A novel pathway for arsenic elimination: human multidrug resistance protein 4 (MRP4\/ABCC4) mediates cellular export of dimethylarsinic acid (DMAV) and the diglutathione conjugate of monomethylarsonous acid (MMAIII)","volume":"86","author":"Banerjee","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.114858_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101583","article-title":"Incidence and mortality of myeloid malignancies in children, adolescents and Young adults in Brazil: a population-based study","volume":"62","author":"Feliciano","year":"2019","journal-title":"Cancer Epidemiol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223006480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:38:58Z","timestamp":1780335538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223006480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":31,"alternative-id":["S0753332223006480"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114858","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Torsemide increases arsenic concentrations by inhibition of multidrug resistance protein 4 in arsenic trioxide treated acute promyelocytic leukemia patients","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114858","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114858"}}